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The effects of bariatric surgery on clinical
profile, DNA methylation, and ageing in
severely obese patients
Eliza Fraszczyk1,2 , Mirjam Luijten2, Annemieke M. W. Spijkerman3, Harold Snieder1, Paul F. K. Wackers2,
Vincent W. Bloks4, Carolina F. Nicoletti5, Carla B. Nonino6, Ana B. Crujeiras7,8, Wim A. Buurman9,
Jan Willem Greve10,11, Sander S. Rensen11, Bruce H. R. Wolffenbuttel12† and Jana V. van Vliet-Ostaptchouk12,13*†
Abstract
Background: Severe obesity is a growing, worldwide burden and conventional therapies including radical change
of diet and/or increased physical activity have limited results. Bariatric surgery has been proposed as an alternative
therapy showing promising results. It leads to substantial weight loss and improvement of comorbidities such as
type 2 diabetes. Increased adiposity is associated with changes in epigenetic profile, including DNA methylation.
We investigated the effect of bariatric surgery on clinical profile, DNA methylation, and biological age estimated
using Horvath’s epigenetic clock.
Results: To determine the impact of bariatric surgery and subsequent weight loss on clinical traits, a cohort of 40
severely obese individuals (BMI = 30–73 kg/m2) was examined at the time of surgery and at three follow-up visits,
i.e., 3, 6, and 12 months after surgery. The majority of the individuals were women (65%) and the mean age at
surgery was 45.1 ± 8.1 years. We observed a significant decrease over time in BMI, fasting glucose, HbA1c, HOMA-IR,
insulin, total cholesterol, triglycerides, LDL and free fatty acids levels, and a significant small increase in HDL levels
(all p values < 0.05). Epigenome-wide association analysis revealed 4857 differentially methylated CpG sites 12
months after surgery (at Bonferroni-corrected p value < 1.09 × 10−7). Including BMI change in the model decreased
the number of significantly differentially methylated CpG sites by 51%. Gene set enrichment analysis identified
overrepresentation of multiple processes including regulation of transcription, RNA metabolic, and biosynthetic
processes in the cell. Bariatric surgery in severely obese patients resulted in a decrease in both biological age and
epigenetic age acceleration (EAA) (mean = − 0.92, p value = 0.039).
Conclusions: Our study shows that bariatric surgery leads to substantial BMI decrease and improvement of clinical
outcomes observed 12 months after surgery. These changes explained part of the association between bariatric
surgery and DNA methylation. We also observed a small, but significant improvement of biological age. These
epigenetic changes may be modifiable by environmental lifestyle factors and could be used as potential biomarkers
for obesity and in the future for obesity related comorbidities.
Keywords: Obesity, Bariatric surgery, Morbid obesity, DNA methylation, Epigenetics, Epigenetic clock, Biological age,
EWAS
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Background
Worldwide prevalence of obesity has nearly tripled since
1975. In 2016, 39% of the adult population were over-
weight (defined as body mass index (BMI) ≥ 25) and 13%
were obese (defined as BMI ≥ 30) making obesity a global
burden [1]. Obesity is recognized as one of the major risk
factors for chronic diseases like cardiovascular disease and
type 2 diabetes, as well as cancer and depression [2]. It is
often accompanied by chronic, low grade inflammation,
high levels of pro-inflammatory cytokines, and low levels
of anti-inflammatory adipokines [3].
Conventional treatment of severe obesity includes
intensive lifestyle modifications such as a radical change
in diet and/or increased physical activity [4]. However,
those interventions are often insufficient, while the pos-
sibilities for pharmacological treatment are limited [5, 6].
Recently, bariatric surgery has been introduced as an
alternative therapy. This involves a variety of surgical
procedures, which results in weight loss and subsequent
improvement of obesity-related co-morbidities [7].
Long-term studies have shown that bariatric surgery can
reduce hyperglycemia or even introduce diabetes remis-
sion in obese patients with type 2 diabetes [8]. Such
metabolic improvement has been observed even before
weight loss has occurred [9]. The mechanisms under-
lying metabolic improvement after bariatric surgery are
not fully understood yet, but epigenetic factors have
been proposed to play a significant role [10, 11]. This is
because the obesity-related metabolic disturbances are
produced as a result of an interaction between environ-
mental, lifestyle, and genetic factors and epigenetics me-
diates the environmental effect on the cellular function
of the organism [12]. One of the most studied epigenetic
mechanisms is DNA methylation, which includes methyl
group binding to the cytosines of cytosine-guanine dinu-
cleotides (CpG sites) [13]. It has been shown that DNA
methylation can be influenced by environmental and
lifestyle factors, including smoking and unhealthy diet
[14, 15]. Also, alterations in DNA methylation levels
have been shown to be a consequence of increased adi-
posity [16] and this epigenetic mechanism was proposed
as a potential link between obesity and its comorbidities
such as insulin resistance [17] and cancer [18, 19].
Therefore, we hypothesized that weight loss resulting
from bariatric surgery may lead to changes in DNA
methylation profiles, potentially providing insight into
molecular mechanisms underlying weight loss–induced
metabolic improvement.
Together with obesity, aging is a risk factor for many
chronic diseases [20]. A recently developed biological age
estimator based on DNA methylation known as epigenetic
clock has been repeatedly shown to be associated with
many age-related conditions such as cancer, neurodegen-
eration, and menopause [21–23], but also with BMI and
obesity [20, 24]. The difference between DNA methylation
age, also referred to as biological age, and chronological
age is called age acceleration. Positive or negative values
of epigenetic age acceleration (EAA) suggest that a specific
tissue is aging faster or slower than expected. To date,
EAA has been associated with level of education, diet, and
other lifestyle factors [25]. Here we hypothesized that EA,
which represents biological age, is higher in severely obese
patients before than after bariatric surgery.
The present study aims to investigate the effect of bar-
iatric surgery on (a) anthropometric, metabolic, and lipid
changes at three time points after surgery (3, 6, and 12
months); (b) changes in DNA methylation by comparing
methylation profiles in peripheral blood just before and
12 months after surgery; (c) biological age and epigenetic
age acceleration (EAA) by comparing these just before
surgery and 12 months after the surgery.
Methods
Study population
A group of 40 severely obese patients underwent elective
bariatric surgery (See Additional file 1: Table S1 for
details of the surgery) at the Department of General Sur-
gery, Maastricht University Medical Center (Maastricht,
the Netherlands). We included baseline and follow-up
data (3, 6, and 12 months after the surgery) for these in-
dividuals. Details of the study can be found elsewhere
[26, 27]. This study was approved by the Medical Ethics
Board of Maastricht University Medical Centre, in line
with the ethical guidelines of the 1975 Declaration of
Helsinki. Informed consent was obtained from each
participant.
Measurements
A standardized protocol was used to obtain blood pressure
and anthropometric measurements such as height, weight,
and waist circumference. Blood samples were collected
after 8 h fasting on the morning of surgery for determining
fasting blood glucose, HbA1c, insulin, homeostatic model
assessment (HOMA-IR), total cholesterol, HDL choles-
terol, LDL cholesterol, triglycerides (TG), free fatty acids
(FFA), alanine transaminase (ALAT), aspartate transami-
nase (ASAT), and C-reactive protein (CRP).
DNA was isolated from whole blood samples collected
at two time points, i.e., on the morning of surgery and
12 months after surgery. A total of 500 ng of genomic
DNA was bisulfite converted using the EZ DNA Methy-
lation kit (Zymo Research, Irvine, CA, USA) and hybrid-
ized to Illumina 450 K arrays (San Diego, CA, USA)
according to the manufacturer’s protocols. Data were
generated by the Genome Analysis Facility of UMCG
(www.rug.nl/research/genetics/genomeanalysisfacility/),
using the same batch of arrays for all study participants.
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DNA methylation quality control and normalization
Handling, analysis, and visualization of the data were
performed in R statistical software version 3.5.1 (http://
cran.r-project.org). Raw signal intensities were imported
in R and subsequently subjected to quality control using
the minfi package [28]. These quality checks revealed no
major batch effects. The functional normalization
method was used to normalize the data using the stand-
ard Illumina probe design information (IlluminaHuman-
Methylation450k array) [29]. Additional probe filtering
was performed to remove from the dataset probes con-
taining a SNP in the probes sequence, probes with a
poor detection p value (p > 0.001), and probes on X and
Y chromosomes. We checked for the presence of ex-
treme outliers in the methylation data (< 25th percentile
− 3IQR (interquartile range) or > 75th percentile +
3IQR) as suggested by the PACE consortium [30]. This
resulted in the removal of 19 additional probes (if out-
liers were detected in > 20% of samples), and setting all
identified outliers to missing values. The final dataset for
analysis included 456,073 probes.
Statistical analysis
Clinical changes
Linear mixed models were used to calculate the overall
significance of clinical changes over time since baseline,
with a random intercept, random coefficient for time,
and an unstructured covariance matrix. CRP and TG
levels were log-transformed since these parameters did
not show normal distribution. All analysis were adjusted
for sex and age differences and calculated using the
“lme4” package in R.
Epigenome-wide association analysis
To find differences in DNA methylation levels within the
same subject over two time points (before and 12 months
after bariatric surgery) we used the limma package for
microarray experiments [31]. Linear regression model
with individual as a random effect was applied. We ad-
justed our analysis for cell type distribution, estimated at 2
time points, before and after surgery, using Houseman’s
estimation method [32]. We also tested if there was a sig-
nificant shift in estimated white blood cell distributions
pre- and post-surgery using a paired t test. Normalized
beta values were logit-transformed into M-values for
downstream analysis because they have been shown to
perform better in smaller studies [33]. As a sensitivity ana-
lysis in those with complete covariate data (n = 30) we ad-
justed our main analysis model for BMI, insulin, glucose,
and CRP changes pre- and post-surgery. We adjusted all
epigenome-wide analyses (EWAS) for multiple testing
using Bonferroni correction. We also calculated the
Pearson correlation between significant CpG sites from
the main analysis and 14 clinical variables, which were
measured pre- and post-surgery (waist-hip ratio, BMI, glu-
cose, insulin, HOMA-IR, HbA1c, total cholesterol, HDL
cholesterol, LDL cholesterol, TG, FFA, ALAT, ASAT,
CRP). We considered a correlation as “moderate to
strong” in case R > 0.5 and p < 0.01.
Replication and comparison to the general population
We attempted to replicate our findings in two independ-
ent cohorts with similar data [34, 35]. Cohort 1 included
11 severely obese patients (7 women and 4 men) who
underwent Roux-en-Y gastric bypass (RYGB) surgery.
Details of the study can be found elsewhere [34]. The
raw DNA methylation data before and 6 months after
the surgery was retrieved from ArrayExpress (https://
www.ebi.ac.uk/arrayexpress/) and the same pipeline for
quality control, normalization, and EWAS analysis as de-
scribed above was applied. Cohort 2 included 24 severely
obese women, who also underwent RYGB. Normalized
DNA methylation beta values and phenotype data before
and 6 months after the surgery was obtained from the
authors of the study [35]. First, we performed EWAS
using the same method as described above. Then, we
looked up our significant CpG sites in the replication
sample results. Finally, we performed a meta-analysis of
all 3 cohorts to find the combined effect of bariatric sur-
gery on DNA methylation. Inverse-variance fixed-effects
meta-analyses of single CpG EWAS results were per-
formed using METAL [36].
Additionally, we compared methylation levels at all
significant CpG sites with healthy lean and healthy obese
people from a general population sample. DNA methyla-
tion data from subsets of the Lifelines cohort including
50 healthy lean (BMI < 25) and 50 healthy obese individ-
uals (BMI > 30, without metabolic complications accord-
ing to the NCEP-ATPIII definition) was available [37].
General details on the Lifelines cohort are described
elsewhere [38, 39]. Methylation profiles in those Lifelines
groups were measured in the same experiment as those
from bariatric surgery patients. We evaluated similarity
to the healthy Lifelines groups by comparing the mean
methylation levels of all significant CpG sites at pre- and
post-surgery with those from the healthy Lifelines
groups. We performed a binomial test to determine the
significance of similarity between cohorts.
Gene set enrichment analysis and association with gene
expression
To find functional interpretation of the results, using the
significant findings from EWAS as input, we performed
gene set enrichment analysis with the “methylGSA” R
package [40] to identify significantly enriched Reactome
pathways with p values for enrichment being adjusted
for multiple testing using false discovery rate (FDR <
5%). Additionally, we used the CpG sites that were
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significantly correlated with clinical traits as input into
the Database for Annotation, Visualization and Inte-
grated Discovery (DAVID 6.7; http://david.abcc.ncifcrf.
gov/summary.jsp) [41] and the MetaCore analysis tool
(GenoGo, Inc.) to find functions of the genes and en-
richment of associated diseases. In DAVID, we used
gene ontology (GOTERM: BP_FAT), followed by Meta-
Core overall enrichment analysis including GO pro-
cesses and enrichment of diseases by biomarkers.
Transcription network analysis in MetaCore was applied
to identify whether subsets of the genes were regulated
by known transcription factors (TFs). Next, we investi-
gated the association between our top significant CpG
sites and gene expression levels in blood using publicly
available eQTMs from the BIOS consortium (https://
www.genenetwork.nl/biosqtlbrowser/).
Epigenetic age analysis
Raw beta-values of the 353 age-related CpG sites were
used to estimate biological age using the DNA methyla-
tion age calculator developed by Horvath [42]. Age
acceleration values for both pre- and post-surgery were
calculated by subtracting the chronological age from the
estimated DNA methylation age, using one tailed paired
t tests to determine the significance of the difference in
age acceleration before and after surgery within the same
individual. p values below 0.05 were considered signifi-
cant for these analyses.
Results
Clinical traits before and after bariatric surgery
To determine the role of bariatric surgery and subse-
quent weight loss on clinical traits, a cohort of 40 se-
verely obese individuals (BMI > 35 kg/m2) was examined
at the time of surgery and at three follow-up visits, i.e.,
3, 6, and 12months after surgery. All clinical and an-
thropometric data collected at baseline and at 3, 6, and
12 months after surgery are presented in Table 1. The
majority of individuals were women (65%) and the mean
age before the surgery was 45.1 ± 8.06. On average, the
levels of many glucose and lipid-related variables, i.e.,
glucose, HbA1c, HOMA-IR, total cholesterol, TG, and
before surgery were elevated compared to blood labora-
tory reference ranges [43]. Overall mean values of clin-
ical measurements for the total study group at baseline
and three follow-up visits are presented in Fig. 1. We ob-
served significantly lower levels over time in BMI, fasting
glucose, Hba1c, HOMA-IR, insulin, total cholesterol,
TG, LDL, and FFA and a significantly, slightly higher
HDL levels. A considerably lower BMI was found 12
months after the bariatric surgery with a mean differ-
ence of − 9.57 kg/m2 (Table 1). At baseline, significant
differences between men and women were found in
waist to hip ratio, HDL cholesterol, FFA, and CRP levels
(Additional file 1: Table S2, p value < 0.05).
In this study population, the mean levels of CRP
decreased steadily after the intervention, suggesting a
Table 1 Baseline characteristics of the severely obese cohort who underwent bariatric surgery






Mean difference 12 months-
baseline (sd)
p value
Sex (females) n, % 26 (65%) 26 (65%) 26 (65%) 26 (65%)
Age (years) 45.1 (8.06) - - 46.1 (8.06)
WHR 1 (0.15)b 1 (0.15) 0.96 (0.13)b 0.97 (0.13)a − 0.06 (0.13) 0.095
BMI kg/m2 45.5 (9.3) 38.3 (9.2)a 35.9 (8.35) − 9.57 (5.9) 5.1 × 10−13
Fasting glucose mmol/L 6.5 (2.2) 5.7 (1.5) 5.3 (1.1)a 5.2 (1.2)b − 1.17 (1.8) 1.6 × 10−4
Insulin ulU/L 17.5 (10.5)a 12.2 (8.7) 9.2 (5.5)b 7.3 (4.4)b − 10.7 (8.3) 1.3 × 10−8
HOMA-IR 5.1 (3.7)a - 2.4 (1.5)c 1.9 (1.1)c − 3.9 (3.7) 9.4 × 10−7
HbA1c % 6.5 (1.1)a 6.1 (0.9) 6 (0.7)b 5.9 (0.9)b − 0.56 (0.8) 0.001
Total cholesterol mmol/L 5.1 (1.1)a 4.6 (0.7) 4.6 (0.8)b 4.5 (1.2)b − 0.63 (0.8) 2.3 × 10−4
HDL mmol/L 1.1 (0.4)a 1.1 (0.4) 1.1 (0.4)b 1.2 (0.4)b 0.16 (0.3) 0.026
LDL mmol/L 3.2 (1)a 3.0 (0.8) 2.7 (0.8)b 2.7 (1)b − 0.57 (0.8) 4.1 × 10−4
TG mmol/L 1.4 [1.0, 2.4]a 1.3 [0.9, 1.8] 0.9 [0.8, 1.8]b 1.1 [0.7, 1.5]b − 0.5 (0.7) 1.4 × 10−6
FFA mmol/L 0.6 (0.3)b 0.6 (0.3) 0.5 (0.2)b 0.5 (0.2)b − 0.10 (0.34) 0.034
ALAT U/L 23.5 (10.2)a 25.6 (10.8) 27 (20.9)b 24.3 (10.8)b 2.5 (12.1) 0.650
ASAT U/L 22.1 (9.2)a 19.3 (6.7) 22.9 (15)b 17.4 (7.1)b − 3.7 (11.2) 0.064
CRP mg/L 7.6 [3.2,16.5]a 4.8 [1.6, 11.5] 3.4 [1.7,5.5]c 1.4 [1, 2.9]b − 4.8 (10) 8.8 × 10−7
Data shown as mean (sd) for normally distributed variables, as median [25%, 75%] for not normally distributed variables and as n (%) for categorical variables, p
value is calculated using mixed models
a1–5 NA’s
b6–10 NA’s
c > 10 NA’s
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decrease in chronic inflammation status (Fig. 1, Table 1).
37.5% of the individuals included in the study had dia-
betes at the pre-surgical state. We observed an improve-
ment in hyperglycemia reflected by significant reduction
in fasting glucose (mean decrease − 1.17 mmol/L) and
HbA1c (mean decrease − 0.6 %) 12 months after surgery
(p value trend over time < 0.001; Table 1). The HOMA-
IR index of insulin resistance and β-cell function was
improved after the surgery (mean decrease − 3.9; p value
trend over time = 9.4−10−7, Table 1).
DNA methylation before and after bariatric surgery
EWAS analysis
DNA methylation analysis of peripheral blood was con-
ducted for two time points, i.e., before and 12 months
after surgery. Epigenome-wide association analysis re-
vealed 4857 significantly differentially methylated CpG
sites 12 months after surgery (at Bonferroni-corrected p
value < 1.09 × 10−7; Additional file 1: Table S3; model
adjusted for age, sex, cell type distribution, and batch ef-
fects). All significant CpG sites showed higher methyla-
tion levels after surgery (mean beta change from 0.01%
up till 15%; Additional file 2: Figure S1) and were dis-
tributed across all chromosomes (Additional file 2: Fig-
ure S2). Among the significantly differentially
methylated CpG sites, we identified significant enrich-
ment of CpG sites located in gene promoter regions, in
5’UTR and in the 1st exon, but also in CpG islands com-
pared to the total array (all p values < 2.2 × 10−16
based on Fisher’s exact test; Additional file 2: Figure
S3).
Estimation of the white blood cell type distribution
using the method by Houseman [32] revealed a clear
shift from pre-surgery to post-surgery. This shift, shown
in Additional file 2: Figure S4, was statistically significant
(p value < 0.01) for all estimated cell types, including
Fig. 1 Mean trends over time (at baseline and the three follow-up visits, i.e., 3, 6, and 12 months) in clinical measurements for severely obese
patients. a Anthropometric traits; b glycemic traits; c lipids traits; d liver enzymes and CRP; presented as mean values of clinical measurements
over four time points. Trends over time were calculated using mixed models; p values: ns, not significant, *< 0.05, **< 0.01, ***< 0.001
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granulocytes, monocytes, B cells, NKs, CD8T’s, and
CDT4’s.
EWAS sensitivity analysis
As a sensitivity analysis, we adjusted our main model for
changes in BMI, insulin, glucose, and CRP (12 months
after the surgery time point versus the baseline), using a
subset of 30 samples with complete covariate data. We
found 3649 significant CpG sites in the base model
adjusted for cell types. After separate adjustments for
change in single traits, we observed a decrease of 6–54%
in the number of significant CpG sites associated with
bariatric surgery, with the largest effects of BMI and in-
sulin. Adding all covariates in a single model decreased
the number of significant CpG sites by 62% (Table 2,
Venn diagram in Additional file 2: Figure S5).
Correlations between post-surgery epigenetic changes and
clinical profile
In order to decipher presumably clinically relevant CpG
sites, we calculated correlations between DNA methyla-
tion change on 4857 significant CpG sites and changes
in clinical traits. We found 420 unique significant cor-
relations between CpGs and post-bariatric changes
(correlation coefficient R > 0.5, p < 0.01), among which
33 CpG sites correlated with more than one trait
(Additional file 1: Table S4).
Gene Set Enrichment analysis
Gene set enrichment analysis, as one of the possible
types of post-EWAS analysis, has previously been shown
to help functionally interpret the results of genome-wide
association studies (GWAS) [44]. Among the 4857
significant CpG sites, we identified overrepresentation of
genes in developmental biology, cell cycle, and cytokine
signaling in immune system pathways (Additional file 1:
Table S5).
Next, we focused on 420 significant CpG sites corre-
lated with clinical traits, which are more likely to have
clinical relevance (Additional file 1: Table S4). We ana-
lyzed the 365 annotated genes to the 420 CpG sites
using DAVID and MetaCore. In GO processes analyzed
by DAVID we identified enrichment of regulation of
transcription, RNA metabolic processes, cellular bio-
synthetic processes (Additional file 1: Table S6, p <
FDR5%). This was further confirmed by GO analysis
performed in MetaCore (Additional file 1: Table S7).
Next, we analyzed gene-disease associations and identi-
fied enrichment of genes for pituitary ACTH hypersecre-
tion, musculoskeletal abnormalities, and morbid obesity
(FDR 5%, Additional file 1: Table S8). Transcription
factors enrichment analysis revealed two highly active
transcription factors, TCF7L1 and LMO2, regulating 90
and 128 genes, respectively (Additional file 1: Table S9
and Additional file 1: Table S10). A look-up of all 4857
CpG sites in the eQTM dataset provided at https://www.
genenetwork.nl/biosqtlbrowser/ showed that 38 CpG
sites were associated with gene expression levels of 50
genes (Additional file 1: Table S11). Two CpG sites
(cg13636880 and cg18888520) located within the genes
ZNF586 and ZSCAN18, respectively, were associated
with gene expression of multiple zinc finger genes,
which are known to be involved in regulation of
transcription, DNA binding, and metal ion binding [45].
Replication of significant CpG sites associated with bariatric
surgery
DNA methylation data from two independent cohorts
was available for replication purposes. We looked up our
top 4857 significant CpG sites in results of those two
replication cohorts. The effect sizes, standard errors and
p values can be found in Additional file 1: Table S12.
Our findings could not be replicated in those two add-
itional cohorts. This was confirmed in the meta-analysis,
which combined results of all three cohorts. The com-
bined effects were largely driven by our own results with
high heterogeneity between cohorts (Additional file 1:
Table S12, column U).
DNA methylation levels in patients undergoing bariatric
surgery and the general population
In order to compare DNA methylation levels before and
after bariatric surgery with the general population, DNA
methylation data, obtained in the same experimental
batch, was available for two healthy groups from the
Lifelines cohort: a lean subgroup and subgroup that was
considered healthy obese (n = 50 each, clinical charac-
teristics are shown in Additional file 1: Table S13). The
1 year post-surgery levels of DNA methylation were
found to be more similar to those observed for the
healthy groups for all 4857 significant CpG sites, than
the pre-surgical levels (p values < 2.2 × 10−16). This is
illustrated by Additional file 2: Figure S6, which shows
Table 2 Number of significant differentially methylated CpG
sites before and after the surgery before and after adjustment
for clinical variables (n = 30).
Model Number of Bonferroni corrected
significant CpG sites (% decrease
from model 1)
Model 1 (adjusted for cell type
distribution)
3649
Model 1 + BMI 1813 (51%)
Model 1 + insulin 1686 (54%)
Model 1 + CRP 3294 (10%)
Model 1 + glucose 3415 (6%)
Model 1 + BMI+ insulin + CRP +
glucose
1386 (62%)
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the methylation levels for the top 15 significant CpG
sites from EWAS analysis in pre- and post-surgical
patients and the two Lifelines subgroups.
Epigenetic age and epigenetic age acceleration before and
after bariatric surgery
For all 40 patients, epigenetic age (EA) was calculated
using the DNA methylation age calculator developed by
Horvath. Before surgery, the mean EA was 3.17 years
higher compared to the chronological age, while after
surgery, the mean EA was 2.26 years higher compared to
the chronological age (Table 3). Based on the individuals
EA, the mean difference between pre- and post-surgery
was 0.08 years, while chronologically, approximately one
year had passed. Epigenetic age acceleration (EAA),
commonly defined as the difference between EA and
chronological age, was smaller after surgery (mean = − 0.92,
p value = 0.039) suggesting significant improvement of
biological age.
Discussion
The aims of the current study were to identify the effects
of bariatric surgery on three domains: clinical profile,
DNA methylation, and biological age. We report signifi-
cant changes in clinical profile at 3, 6, and 12 months
after the surgery and in DNA methylation profile and
biological age 12 months after surgery, suggesting that
bariatric surgery has a prominent effect on individual
health and epigenetics.
Beneficial effects of bariatric surgery on weight and
clinical profile
After bariatric surgery, we observed a sustained decrease
in BMI, reflecting substantial weight loss in response to
the intervention. A considerable decrease in BMI was
also observed within the first year after the surgery in
other similar studies [46–48]. In the CBS longitudinal
cohort study, the peak weight decrease was reached 2
years after surgery and remained stable for at least 20
years [47]. Over 60% of patients included in our study
underwent RYGB, which is the preferable method of
bariatric surgery due to greater weight loss and higher
diabetes remission rate (62% vs. 47% and 80.3% vs.
56.7%, respectively) compared to a gastric banding pro-
cedure [9, 49]. In our analysis, we combined all types of
the surgery to increase the power of the study. As a sen-
sitivity analysis, we repeated the analysis in the largest
group (RYGB) and found similar results with less signifi-
cant p values (all EWAS significant CpG sites, n = 4857,
p values < 1 × 10−4; correlation of effect sizes between
RYGB group and total group including all types of
surgery was 0.99; data not shown).
Severe obesity is a known risk factor for type 2 dia-
betes and nearly 50% of type 2 diabetes patients are
obese [50]. Risk of developing diabetes is even 20 times
higher in obese than in lean individuals [51]. In line
with these data, elevated levels of glucose, HbA1c, in-
sulin, and HOMA-IR in the patients before the surgery
suggest either pre-diabetic state or fully developed type
2 diabetes in 37.5% of severely obese patients. In our
study, we observed improvement in post-operation
glycemic profile: fasting glucose and insulin levels in
blood were significantly lower over time within the
first year after the surgery. The early improvement in
glycemic traits observed in our study may be asso-
ciated with caloric restriction leading to increased hep-
atic insulin sensitivity and improved beta cell function,
also related to the post-bariatric high postprandial
glucagon-like peptide 1 secretion [52]. Later, weight
loss induces improvement in muscle insulin sensitivity,
which enhances overall insulin sensitivity and glucose
tolerance [53].
Hyperlipidemia, hypercholesterolemia, and hypertri-
glyceridemia associated with severe obesity are improved
Table 3 Chronological age, epigenetic age (EA), and epigenetic age acceleration (EAA) pre- and post-surgery in severely obese
patients
Mean SD Min Max
Chronological age, pre-surgery (years) 45.10 8.06 29 65
Chronological age, post-surgery (years) 46.10 8.06 30 66
EA, pre-surgery (years) 48.27 9.15 28.37 69.38
EA, post-surgery (years) 48.36 8.67 31.07 65.53
EA change 0.08 3.22 − 8.17 6.92
EAA, difference between epigenetic and
chronological age pre-surgery
3.17 4.71 − 5.72 13.75
EAA, difference between epigenetic and
chronological age post- surgery
2.26 5.05 − 7.47 17.28
Change in EAA − 0.92* 0.34 − 1.75 3.53
*p value = 0.039
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after bariatric surgery in at least 70% of patients [9]. In
our data, we observed similar changes in levels of triglyc-
erides, total, and LDL cholesterol levels after the surgery.
With severe obesity progressing, adipose tissue be-
comes more dysfunctional. Increased production of pro-
inflammatory cytokines in adipose tissue contributes to
systemic inflammation, which is a hallmark of severe
obesity. Elevated FFAs increase insulin secretion in the
pancreas and decreases insulin sensitivity in the liver
and muscle, which contributes to obesity-related meta-
bolic complications [54]. C-reactive protein was signifi-
cantly lower after bariatric surgery, further confirming
reduced inflammation after weight loss.
Epigenetic changes after bariatric surgery
The beneficial effect of bariatric surgery on metabolic
and body composition parameters observed in our study
paralleled a shift in DNA methylation patterns in blood.
As shown previously, DNA methylation levels in blood
can (partly) reflect epigenetic signatures in target tissues
for metabolic diseases such as the adipose tissue, liver,
and muscle [55–57]. Although studies investigating the
effect of bariatric surgery on DNA methylation levels on
a genome-wide level are scarce, we identified one study
in the adipose tissue and one study in blood. In the first
study, fifteen obese women with similar age distribution
to our study underwent gastric bypass surgery and an-
other surgery with a mean follow-up of 17.5 months.
The analysis revealed differentially methylated CpG sites
in omental (15 CpG sites, Bonferroni corrected p value)
and subcutaneous adipose tissue (3601 CpG sites, Bon-
ferroni corrected p value), with higher methylation at
most significant CpG sites before the surgery [58]. In the
second study in blood, however, the direction of differ-
ential methylation was different, 666 CpG sites showed
higher methylation after surgery in 24 women who
underwent RYGB (a mean follow-up 6 months) [35].
Another intervention study investigating the effect of
physical exercise on DNA methylation levels in adipose
tissue found 17,975 differentially methylated individual
CpG sites (based on FDR < 5%), of which 16,470 are
with higher methylation and 1505 are with lower methy-
lation in response to 6 months of exercise in 23 non-
obese men (BMI < 30) [59]. Similar to our observations,
the effects of intervention, although to a lesser degree
than in our study, were weight loss and significant de-
crease in waist circumference and waist to hip ratio. We
hypothesize that weight reduction and related metabolic
and inflammatory changes occurring initially after the
surgery lead to altered DNA methylation levels, similar
to what has been shown in an obesity EWAS using
Mendelian randomization methods, where changes in
DNA methylation levels were likely to be due to changes
in BMI [16].
DNA methylation levels at all significant CpG sites
were higher after bariatric surgery. However, the uni-
directional (hyper) methylation changes were somewhat
unexpected. The results are also unlikely due to a poten-
tial technical bias, since all the steps including DNA
isolation, sample randomization on the plates, bisulfite
conversion, and the hybridization to the chip were per-
formed within the same experimental batch. Interest-
ingly, folic acid deficiency has been reported among
bariatric patients after surgery [60]. Folic acid is the
donor of methyl group, required for DNA methylation
reactions in vivo [61]. Changes in DNA methylation may
partly deplete folate reserves after bariatric surgery and
explain this so-called Great Folate Mystery in bariatric
patients post-surgically together with decreased food in-
take. This hypothesis needs further investigation.
Twelve months after the bariatric surgery, DNA
methylation levels were changed at numerous CpG
sites. Epigenetic mechanisms are modifiable via envir-
onmental exposures and lifestyle factors, therefore,
such a considerable change after bariatric surgery may
have an impact on DNA methylation [62]. In this re-
gard, it was proposed that epigenetic regulation could
mediate the benefit of bariatric surgery on body
weight and the metabolic disturbances associated with
excess body weight, such as insulin resistance, hyper-
tension, and cardiovascular disease [12].
Accordingly, adjusting our analysis for BMI, glucose,
insulin, and CRP changes decreased the number of
significant CpG sites, suggesting that post-operation
changes in clinical profile can explain part of the associ-
ation between bariatric surgery and DNA methylation.
We conclude that DNA methylation changes observed
after bariatric surgery are a result of clinical changes,
including but not limited to weight loss.
We also compared the pre- and post-surgery DNA
methylation levels at top significant CpG sites with DNA
methylation levels in healthy individuals. Our data sug-
gests restoration of the “severe obesity” DNA methylation
patterns 12 months after surgery to the epigenetic profiles
found in general populations. In agreement with these ob-
servations, DNA methylation levels of the SCD gene pro-
moter were found to be lower in morbidly obese subjects
(n = 120) before bariatric surgery but increased 6 months
after RYGB to similar levels as in the control group
(n = 30, BMI similar to after surgery group) [63].
Potential functional relevance of bariatric surgery-
associated methylation
The 420 CpG sites significantly correlated with meta-
bolic traits may represent clinically relevant changes in
DNA methylation. The TF-set enrichment analysis of
those CpG sites annotated to gene names revealed two
interesting transcription factors: TCF7L1 and LMO2.
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TCF7L1 is a transcription factor 7 like 1 involved in the
regulation of cell cycle. It belongs to the same family as
the well-known type 2 diabetes susceptibility gene tran-
scription factor 7 like 2 (TCF7L2) found in multiple
GWAS studies [64]. Additionally, TCF7L2 was associ-
ated with type 2 diabetes in epigenetic studies performed
in blood and pancreas [65, 66]. Proteins of TCF7L1 and
TCF7L2 show similar features and are important for the
regulation of Wnt/β-catenin signaling during adipocyte
development [67, 68]. The LMO2 (LIM Domain Only 2)
protein has a crucial role in hematopoietic development
and is associated with leukemia [69]. Further studies are
needed to elucidate the role of the epigenetic regulation
of LM02 in the field of obesity and metabolic disorders.
To the best of our knowledge, this is the first study
which shows an impact of bariatric surgery on biological
(epigenetic) age. The only other study we identified was
conducted in the liver tissue which showed that despite
a rapid decrease in BMI in a 9-month period, the epi-
genetic age was not reversed [70]. Although we observed
a minor improvement in biological age after surgery, the
biological age of the patients studied remained increased
compared to the chronological age. Other studies have
shown BMI to be associated with increased EAA in
blood and buccal cells [24, 71]. In our study, the EAA,
as expected, significantly decreased upon surgery,
suggesting improvement of biological age together with
improvement of clinical factors after bariatric surgery.
Strengths and limitations
The strength of our study is its longitudinal setting, where
bariatric patients were examined at multiple time points.
Due to the dynamic nature of epigenetic markers, the
EWAS analysis was conducted at 2 time points (before and
12 months after the surgery) to unravel the effect of the
bariatric surgery on the DNA methylation profile. Al-
though we realized that the follow-up period of 12 months
is relatively short, we still observed major changes in clin-
ical and epigenetic profile. Many other studies focused on
women, while our population was mixed, making it pos-
sible to extend those findings to males. Using blood as a
tissue for conducting EWAS is a limitation in our study,
however, metabolically active tissues are difficult to obtain.
Additionally, we adjusted our analysis for blood cell types,
knowing that DNA methylation can vary per cell type. We
also list a relatively small sample size as another limitation
of our study. Unfortunately, we were not able to replicate
our findings in two independent cohorts. We observed
high heterogeneity in effect sizes between cohorts, which
may be related to shorter follow-up time (6 instead of 12
months), substantially smaller sample sizes and power (40
vs. 24 and 11) or other design differences between dis-
covery and replication studies. Interestingly, DNA methyla-
tion patterns after the surgery were more similar to general
population levels, suggesting a restoration of more healthy
DNA methylation levels 12 months after the surgery.
Conclusions
In summary, our study shows that bariatric surgery leads
to improvement of clinical outcomes, including substan-
tial decrease in BMI, as well as to epigenetic changes.
Such drastic intervention may restore DNA methylation
profiles in patients with severe obesity towards the pat-
terns observed in healthy subjects. The beneficial effect
of bariatric surgery on changes in DNA methylation
markers could be mediated by body weight and meta-
bolic parameters and in the future, those markers may
be useful for obesity-related comorbidities.
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